| Title |
Continuous infusion of enzyme replacement therapy is inferior to weekly infusions in MPS I dogs
|
|---|---|
| Published in |
Journal of Inherited Metabolic Disease, June 2009
|
| DOI | 10.1007/s10545-009-1198-5 |
| Pubmed ID | |
| Authors |
M. B. Passage, A. W. Krieger, M. C. Peinovich, T. Lester, S. Q. Le, P. I. Dickson, E. D. Kakkis |
| Abstract |
Intravenous enzyme replacement therapy with recombinant human α-L-iduronidase (rhIDU) is used weekly to treat mucopolysaccharidosis (MPS) I. We tested continuous administration of rhIDU at two dosing levels (0.58 mg/kg per week and 2 mg/kg per week) in MPS I dogs, and compared the efficacy of continuous infusion with the clinically used 0.58 mg/kg weekly three-hour infusion. Peak plasma concentrations of rhIDU were much higher in weekly-treated dogs (mean 256 units/ml) than steady-state concentrations in dogs treated with continuous infusion (mean 1.97 units/ml at 0.58 mg/kg per week; 8.44 units/ml at 2 mg/kg per week). Dogs receiving continuous IV rhIDU, even at a higher (2 mg/kg per week) dose, had consistently lower iduronidase levels in tissues than dogs receiving a weekly (0.58 mg/kg per week) dose. GAG storage was also less improved by continuous intravenous infusion. Adverse events were similar in all dosing groups. We found that continuous administration of 2 mg/kg per week rhIDU to MPS I dogs was insufficient to achieve GAG storage reduction comparable to 0.58 mg/kg weekly dosing. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 29% |
| Student > Master | 2 | 14% |
| Researcher | 2 | 14% |
| Student > Ph. D. Student | 1 | 7% |
| Student > Doctoral Student | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 3 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 50% |
| Biochemistry, Genetics and Molecular Biology | 2 | 14% |
| Agricultural and Biological Sciences | 1 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Unknown | 3 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 August 2013.
All research outputs
#14,629,021
of 22,715,151 outputs
Outputs from Journal of Inherited Metabolic Disease
#1,402
of 1,838 outputs
Outputs of similar age
#92,974
of 110,522 outputs
Outputs of similar age from Journal of Inherited Metabolic Disease
#5
of 7 outputs
Altmetric has tracked 22,715,151 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,838 research outputs from this source. They receive a mean Attention Score of 4.6. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 110,522 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.